NCT05076253.

Methods	Trial design: triple‐blind RCT with 2 parallel arms Type of record: trial register entry Sample size: 72 Setting: inpatient Country: Thailand Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: NCT05076253 Date of registration: 13 October 2021
Participants	Inclusion criteria Adult men and women age 18‐80 years Non‐pregnant or breast‐feeding women Had mild to moderate symptoms as defined by the WHO severity score for COVID‐19 Exclusion criteria Were allergic to ivermectin Have the potential for a drug‐drug interaction with ivermectin such as tamoxifen or warfarin Previously treated with ivermectin in the last 7 days Had received any herbal medicine Had severe chronic illness (severe congestive heart failure, chronic kidney disease stage 4‐5, chronic liver disease, terminal cancer diseases) Had concurrent bacterial infection or unwilling to participate in the trial Patients with severe symptoms, likely due to cytokine release syndrome Uncontrolled comorbidities and immunocompromized states
Interventions	Details of intervention Type and dose: ivermectin 12 mg, once daily for 5 days Route of administration: oral Treatment details of control group Placebo Concomitant therapy: standard of care including favipiravir or andrographolide, corticosteroids, cetrizine and paracetamol administered in both study arms
Outcomes	Primary study outcome Viral clearance of SARS‐ CoV‐2 intervention in 7 days and 14 days Relevant review outcomes planned Viral clearance of SARS‐ CoV‐2 intervention in 7 days and 14 days Mortality rate in 28 days Additional study outcomes Duration of hospitalization Frequency of clinical worsening in 28 days Need for mechanical ventilation in 28 days Mortality rate in 28 days
Notes	Reason for awaiting classification: study completed, but results not published yet Recruitment status: completed Prospective completion date: December 2021, study completed Planned completion date more than 6 months ago: no Date last update posted: 15 December 2021 Sponsor/funding: Bangkok Metropolitan Administration Medical College and Vajira Hospital